RSV vaccine for pregnant women: benefits for babies in Scotland
Treatments studied
Part of Infections clinical trials.
This study looks at how well the RSV vaccine given to pregnant women (called ABRYSVO) protects babies from getting RSV after birth. It uses national health data from Scotland to track health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby was born in Scotland between September 1, 2024 and February 28, 2026
- Baby was born at 28 weeks of pregnancy or later
- The mother did not receive any other RSV vaccine during pregnancy
- Baby does not qualify for monoclonal antibody (RSV preventive medicine) per UK guidelines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This study tests two approved ways to prevent RSV, a common virus that can make babies very sick. Pregnant women may get a vaccine, and/or their babies may get an antibody shot after birth. The study compares these options to see which works best.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
This study tests whether a second dose of the RSV vaccine during a new pregnancy protects you and your baby from RSV. If you received the RSVpreF or Abrysvo vaccine in a past pregnancy, you may be able to join.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.